Dalbavancin - A novel lipoglycopeptide antimicrobial for gram positive pathogens

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2008, Pages 78-88

  Das, Biswadeep ^a   Sarkar, Chayna ^a   Biswas, Rakesh ^b   Pandey, Sureshwar ^a  

^a AIMST UNIVERSITY   (Malaysia)

^b MELAKA MANIPAL MEDICAL COLLEGE   (India)

Author keywords

Dalbavancin; Gram positive organisms; Lipoglycopeptide; Multidrug resistant; Staphylococcus aureus

Indexed keywords

A A1; CEFAZOLIN; CEFTRIAXONE; CLINDAMYCIN; DALBAVANCIN; LINEZOLID; MDL 63397; PLACEBO; UNCLASSIFIED DRUG; VANCOMYCIN; VER 001; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; TEICOPLANIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CATHETER INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG WITHDRAWAL; GASTROINTESTINAL INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; RED MAN SYNDROME; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; BACTERIAL INFECTION; DRUG EFFECT; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; TEICOPLANIN;

EID: 41649095277     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Andes DR and Craig WA (2004). In vivo pharmacodynamic characterization of dalbavancin (DAL) in the murine thigh infection model [abstr]. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.39.
2. Anon (2005). Pfizer Inc: Pfizer completes acquisition of Vicuron pharmaceuticals. Press release: September 14.
3. Anon (2002). Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal.Wkly. Rep., 51(26): 565-567.
4. Anon (1994). Summary of notifiable diseases, United States 1994. MMWR Morb. Mortal.Wkly. Rep., 43(53): 1-80.
5. Anon (1999). Versicor Inc: Versicor to present at Hambrecht & Quist 17th annual health care conference. Press release, January 13.
6. Anon (2003). Versicor Inc: Vicuron pharmaceuticals is new name for Versicor. Press release, March 26.
7. Anon (2005). Vicuron Pharmaceuticals Inc: Vicuron pharmaceuticals granted priority review of dalbavancin NDA by FDA in complicated skin and soft tissue infection. Press release, February 24.
8. Beauregard DA, Williams DH, Gwynn MN and Knowles DJ (1995). Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother., 39(3): 781-785.
9. Blumberg HM, Rimland D, Carroll DJ, Terry P and Wachsmuth IK (1991). Rapid development of ciprofloxacin resistance in methicillin-susceptible and - resistant Staphylococcus aureus. J. Infect. Dis., 163: 1279-1285.
10. Bowker KE, Noel AR and MacGowan P (2004). Antibacterial effect of dalbavancin against MSSA, MRSA and VISA in an in vitro pharmacokinetic system[abstr]. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.24.
11. Bozdogan B, Ednie L, Credito K, Kosowska K and Appelbaum PC (2004). Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob. Agents Chemother., 48: 4762-4765. (Pubitemid 39577682)
12. Bozdogan B, Esel D, Whitener C, Browne FA and Appelbaum PC (2003). Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus isolated at Hershey Medical Center. J. Antimicrob. Chemother., 52: 864-868. (Pubitemid 37407819)
13. Bulgheroni A, Jabes D, Pollini W, Carrano L, Desperati V, Romagnoli M, Rovida C, Colombo L and Garafalo F (2004). Dalbavancin (DAL) uptake by murine macrophages. ICAAC 44, Abs A1490.
14. Campbell KC, Kelly E, Targovnik N, Hughes L, Van Saders C, Gottlieb AB, Dorr MB and Leighton A (2003). Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J. Am. Acad. Audiol., 14: 157-68; quiz 170-171.
15. Candiani G, Abbondi M, Borgonovi M, Romanò G and Parenti F (1999). In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother., 44: 179-192. (Pubitemid 29389280)
16. Cavaleri M, Riva S, Valagussa A, Guanci M, Colombo L, Dowell J and Stogniew M (2005). Pharmacokinetics and excretion of dalbavancin in the rat. J. Antimicrob. Chemother., 55(Suppl 2): ii31-35.
17. Cosgrove SE and Carmeli Y (2003). The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis., 36(11): 1433-1437.
18. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW and Carmeli Y (2003). Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis., 36(1): 53-59. (Pubitemid 36099097)
19. Darouiche RO and Mansouri MD (2005). Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J. Infect., 50: 206-209.
20. Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, White RJ and Henkel TJ (2005). Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J. Antimicrob. Chemother., 55(Suppl 2): ii25-30. (Pubitemid 40425476)
21. Dowell JA, Seltzer E, Buckwalter M and Marbury T (2004). The pharmacokinetics of dalbavancin (DAL) in subject to mild, moderate or severe hepatic impairment (HI) [abstr]. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.4.
22. th European Congress of Clinical Microbiology and Infectious Disease, May 10-13; Glasgow, UK.
23. Ednie L, Kelly LM, Smith K, Jacobs MR and Appelbaum PC (2003). Antistaphylococcal activity of dalbavancin compared to those of six other agents[abstr]. In: Proceedings of the 43rd International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.1631. (Pubitemid 36254251)
24. Flamm RK, Draghi DC, Karlowsky JA and Sahm DF (2004). Activity of dalbavancin against clinical isolates of staphylococci and streptococci from the US and Europe[abstr]. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.73.
25. Gales AC, Sader HS and Jones RN (2005). Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect., 11: 95-100. (Pubitemid 40253813)
26. Goldstein BP, Seltzer E, Flamm R and Sahm D (2005). Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy [abstr]. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.1577.
27. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Tyrrell K and Fernandez HT (2003). In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob. Agents Chemother., 47: 1968-1971. (Pubitemid 36637823)
28. Goldstein EJC and Citron DM (2005). In vitro activity of dalbavancin and 12 other agents against 338 aerobic and anaerobic gram-positive clinical strains isolated from diabetic foot infections (DFI) [abstr]. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.1749.
29. Guay DR (2004). Dalbavancin: an investigational glycopeptide. Expert Rev. Anti Infect. Ther., 2: 845-852.
30. Hackbarth CJ, Lopez S and Trias J, et al (1999). In vitro activity of the glycopeptide BI-397 against Staphylococcus aureus and Staphylococcus epidermidis [abstract no.1283 ]. 39th Inter Science Conference on Antimicrobial Agents and chemotherapy; Sep 26-28; San Francisco(CA).
31. Heine HS, Bassett J and Miller L (2005). In vitro and in vivo activity of dalbavancin (DAL) against Bacillus anthracis (BA) [abstr]. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.2079.
32. Hershow RC, Khayr WF and Schreckenberger PC (1998). Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. Antimicrob. Agents Chemother., 5: 213-220. (Pubitemid 28373706)
33. Higgins DL, Chang R and Debabov DV et al (2005). Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 49(3): 1127-1134. (Pubitemid 40327734)
34. Hiramatsu K (1998). The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am. J. Med., 104: 7S-10S.
35. Jabes D, Candiani G, Romano G, Brunati C, Riva S and Cavaleri M (2004). Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob. Agents Chemother., 48: 1118-1123. (Pubitemid 38405463)
36. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J and O'Riordan W (2005). Randomized, double-blind comparison of once-weekly dalbavancin versus twice daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis., 41(10): 1407-1415. (Pubitemid 41579981)
37. Jones RN, Biedenbach DJ, Johnson DM and Pfaller MA (2001). In vitro evaluation of BI-397, a novel glycopeptide antimicrobial agent. J. Chemother., 13(3): 244-254.
38. Jones RN, Sader HS, Fritsche TR and Stilwell M (2004). Comparative activity of dalbavancin tested against 7,771 isolates from the U.S.A. and Europe (2003) [abstr]. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.173.
39. Kahne D, Leimkuhler C, Lu W and Walsh C (2005). Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev., 105(2): 425-448.
40. Kim A, Kuti JL and Nicolau DP (2007). Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin. Investig. Drugs, 16(5): 717-733. (Pubitemid 46723274)
41. Kirst HA, Thompson DG and Nicas TI (1998). Historical yearly usage of vancomycin. Antimicrob. Agents Chemother., 42(5): 1303-1304.
42. Lacy CF, Armstrong LL, Goldman MP and Lannce LL eds. (2005). Lexi drugs: comprehensive and specialty fields. Hudson, OH: Lexi Comp, Inc.
43. Lefort A, Pavie J, Garry L, Chau F and Fantin B (2004). Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob. Agents Chemother., 48: 1061-1064. (Pubitemid 38280371)
44. Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KC, Kelly E(2004). Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother., 48: 940-945. (Pubitemid 38280347)
45. Lin G, Credito K, Ednie LM and Appelbaum PC (2005). Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob. Agents Chemother., 49: 770-772. (Pubitemid 40175692)
46. Lin SW, Carver PL and DePestel DD (2006). Dalbavancin: A new option for the treatment of Gram-positive infections. Ann. Pharmacother., 40(3): 449-460.
47. Linde HJ, Schmidt M, Fuchs E, Reischl U, Niller HH and Lehn N (2001). In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob. Agents Chemother., 45: 1553-1557. (Pubitemid 32374134)
48. Lopez S, Hackbarth C, Romano G, Trias J, Jabes D and Goldstein BP (2005). In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J. Antimicrob. Chemother., 55(Suppl 2): ii21-24. (Pubitemid 40425475)
49. Malabarba A and Ciabatti R (2001). Glycopeptide derivatives. Curr. Med. Chem., 8(14): 1759-1773.
50. Malabarba A and Goldstein BP (2005). Origin, structure, and activity in vitro and in vivo of dalbavancin. J. Antimicrob. Chemother., 55(Suppl 2: ii): 15-20. (Pubitemid 40425474)
51. McEvoy GK ed. (2005). Glycopeptides. AHFS drug formulation 2005.Bethesda, MD: American Society of Health-System Pharmacists, Inc., pp.464-471.
52. Mushtaq S, Warner M, Johnson AP and Livermore DM (2004). Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J. Antimicrob. Chemother., 54: 617-620. (Pubitemid 39263902)
53. Nichols RL (1999). Optimal treatment of complicated skin and soft tissue infections. J. Antimicrob. Chemother., 44: 19-23. (Pubitemid 29425488)
54. Novak R. Henriques B, Charpentier E. Normark S and Tuomanen E (1999). Emergence of vancomycin tolerance in Streptococcus pneumoniae [comments]. Nature, 399(6736): 590-593. (Pubitemid 29279179)
55. Pace JL and Yang G (2006). Glycopeptides: update on an old successful antibiotic class. Biochem. Pharmacol., 71(7): 968-980.
56. Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, Goldstein B, Henkel T and Seltzer E (2005). Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by grampositive pathogens. Clin. Infect. Dis., 40: 374-380. (Pubitemid 40216504)
57. Schmitz F-J, Fluit A, Brisse S, Verhoef J, Koher K and Milatovic D (1999). Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol., 26: 81-87.
58. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA and Henkel T (2003). Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis., 37: 1298-1303.
59. Seltzer E, Goldberg L and Krause D (2005). Safety of dalbavancin (DAL) in a clinical development program [abstr]. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.1576.
60. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Bank JD, White E and Jarvis WR (1999). Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.[comment]. N. Engl. J. Med., 340(7): 493-501.
61. Spellberg B, Powers JH, Brass EP, Miller LG and Edwards JE Jr. (2004). Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis., 38(9): 1279-1286. (Pubitemid 38608571)
62. Stephen J, Jones RN, Sader HS and Fritsche TR (2003). Worldwide assessment of dalbavancin (BI397) activity and spectrum (2002) [abstr]. In: Proceedings of the 43rd International Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society of Microbiology, p.2107.
63. Streit JM, Fritsche TR, Sader HS and Jones RN (2004). Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis., 48: 137-143.
64. Van Bambeke F (2004). Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol., 4(5): 471-478. (Pubitemid 40533007)
65. Van Bambeke F, Laethem YV, Courvalin P and Tulkens PM (2004). Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs, 64(9): 913-936. (Pubitemid 38608472)
66. Voss A, Milatovic D, Wallrauch-Schwarz, Rosdahl VT and Braveny I (1994). Methicillin-resistant Staphylococcus aureus in Europe. Eur. J. Clin. Microbiol. Infect. Dis., 13: 50-55.